VIRAGE Trial: Theriva Biologics Presents Phase 2b VCN-01 Combo Therapy for Pancreatic Cancer at ASCO 2024

Theriva Biologics, a company focused on developing treatments for cancer and other serious diseases, has announced that its Phase 2b clinical trial, known as VIRAGE, will be presented at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting. The trial investigates the drug VCN-01, which is administered alongside standard chemotherapy for patients newly diagnosed with metastatic pancreatic cancer. The study is a randomized, open-label, and placebo-controlled multicenter trial that aims to assess the effectiveness of VCN-01 in combination with gemcitabine/nab-paclitaxel as a first-line therapy.

The ASCO presentation will be led by Dr. Rocío García-Carbonero and will take place during the poster session dedicated to gastrointestinal cancers. The session is scheduled for June 1, 2024, from 1:30 PM to 4:30 PM US CDT. The abstract for this presentation has been assigned the number TPS4210.

Theriva Biologics is advancing a novel oncolytic adenovirus platform for various modes of delivery, aiming to trigger tumor cell death and enhance the body's immune response to cancer. The company's lead product, VCN-01, is an oncolytic adenovirus that selectively replicates within tumor cells and breaks down the tumor stroma barrier, which is a significant impediment to cancer treatment. The company also has other candidates in development, such as SYN-004, designed to degrade IV antibiotics in the GI tract to prevent microbiome damage and SYN-020, an oral formulation of an enzyme intended to treat both local and systemic GI diseases.

The company's mission is to address areas with high unmet medical needs, and it is committed to advancing its therapeutics through clinical trials to bring new treatment options to patients.